09/21/2026 01:00
UVJC to Launch NovaJet at WESEMiBAY as Semiconductor Industry Looks Beyond Traditional Scaling

Universal Vapor Jet Corporation (UVJC), a wholly-owned subsidiary of Universal Display Corporation (UDC) (Nasdaq: OLED), is set to unveil NovaJet, the first commercial system built on its proprietary Universal Vapor Jet Printing (UVJP) platform, at the WESEMiBAY Semiconductor Ecosystem Conference and Expo in Shenzhen, China, from 14 to 16 October 2026. The launch marks UVJC’s first trade show appearance and introduces the company’s dry, solvent-free and maskless approach to thin-film depositi...

09/15/2026 04:00
Signaloid joins Open Chiplet Atlas Alliance and Announces Plans to Make Its UxHw ASICs Available via OCA Ecosystem

British compute hardware company Signaloid has joined the Open Chiplet Atlas (OCA) and announced plans to make its UxHw® compute acceleration technology available as chiplets within the OCA ecosystem. The UxHw technology targets AI and simulation workloads that rely on stochastic methods, including quantitative finance, reinforcement learning, engineering simulations, and world models. The announcement follows Signaloid’s recent tapeout of a UxHw ASIC for robotics and physical AI in an ultra-lo...

08/04/2026 04:52
Kioxia Announces KIOXIA GP1 Series Super High IOPS SSDs for AI Applications

Kioxia Corporation today announced the KIOXIA GP1 Series PCIe® 6.0 NVMe™ SSDs, the first product in its KIOXIA GP Series of Super High IOPS SSDs optimized for GPU direct access. Building on the KIOXIA GP Series technology introduced earlier this year1, the KIOXIA GP1 Series delivers up to 10 million random read IOPS2 using KIOXIA XL-FLASH™ generation 2 flash memory, enabling flash-based memory extension to help address the growing performance and memory demands of AI infrastructure. Evaluation ...

08/04/2026 05:00
4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis

4Moving Biotech (4MB), a clinical-stage biotechnology company dedicated to developing first-in-class therapies for inflammatory knee osteoarthritis, today announced the completion of patient enrollment in INFLAM MOTION, its international Phase 2a proof-of-concept study. The trial is evaluating the efficacy and safety of 4P004, an investigational intra-articular GLP-1 receptor agonist designed to address the inflammatory mechanisms underlying both symptoms and disease progression in knee osteoar...